Openbookopenbook
Equity
StockUS listing USARGXNASDAQHealthcareQuality Compounder

argenx NV ADR(ARGX) Stock Analysis | Healthcare

USD --+0.00%
Reward71High
Risk18Low
75%Data
Strong 32% profit margin · Revenue growing 59% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 51.48Bn
Reward Ratingⓘ71 High reward assessment · 75% data coverage
Top 25% of stocksView factors
Risk Ratingⓘ18 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ARGX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is argenx NV ADR?

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.

AI Brief Pro

The brief on argenx NV ADR

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is argenx NV ADR?

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 51.48B, and a P/E ratio of 31.2x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: High (71)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

UCBJFLarge Cap / 58.1B market cap
UCB SA
Compare
CMXHFLarge Cap / 63.5B market cap
CSL Limited
Compare
RVMDLarge Cap / 40.7B market cap
Revolution Medicines Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap51.48B
P/E Ratio31.1978
Dividend YieldN/A
Beta-0.043
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.